Ann Lab Med 2019; 39(2): 200-204
Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified
Hyoeun Shim, M.D.1, Seongsoo Jang, M.D.2, Jooryung Huh, M.D.3, Dok Hyun Yoon, M.D.4, Cheolwon Suh, M.D.4, and Chan-Jeoung Park, M.D.2
1Department of Laboratory Medicine, National Cancer Center, Goyang, Korea; Departments of 2Laboratory Medicine, 3Pathology and 4Oncology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
Corresponding author: Chan-Jeoung Park, M.D.
Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 05505, Korea
Tel: +82-2-3010-4508
Fax: +82-2-478-0884
Received: February 25, 2018; Revised: May 1, 2018; Accepted: September 27, 2018; Published online: March 1, 2019.
© Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Assessment of bone marrow (BM) involvement in peripheral T-cell lymphoma, not otherwise specified (PTCL) is straightforward in cases of extensive involvement but difficult in cases of minimal to partial involvement. We evaluated the usefulness of CD3 as an immunohistochemical marker for assessing BM involvement in PTCL patients. BM biopsies of 92 PTCL patients were immunohistochemically stained for CD3, CD4, CD8, CD20, and CD56, and evaluated by two hematopathologists. CD3 positivity was graded according to the proportion of CD3-positive cells and the number of CD3-positive cells in a cluster. These criteria were used to determine the cut-offs at which significant differences in progression-free survival (PFS) and overall survival (OS) were observed. Multivariate analysis controlling the International Prognostic Index (IPI) score and its individual factors revealed that >20 CD3-positive cells in a cluster adversely affected PFS (relative risk [RR], 2.1; 95% confidence interval [CI], 1.0–4.3; P=0.047) and OS (RR, 2.4; 95% CI, 1.1–5.1; P=0.028) independent of IPI score. A cluster with >20 CD3-positive cells is a candidate indicator for BM involvement in PTCL.
Keywords: Peripheral T-cell lymphoma, Bone marrow involvement, CD3 positivity

This Article



Indexed/Covered by